 |
v2.4.0.6
|
Accounts Receivable (Details 1) (USD $)
|
6 Months Ended |
|
Oct. 31, 2012
|
Oct. 31, 2011
|
| Roll forward of each significant accounts receivable estimate |
|
|
| Valuation Allowances and Reserves, Balance, Beginning Balance |
$ 18,035,000 |
$ 17,100,000 |
| Current Provision |
100,293,000 |
86,883,000 |
| Actual Credits in Current Period |
(96,979,000) |
(85,341,000) |
| Valuation Allowances and Reserves, Balance, Ending Balance |
21,349,000 |
18,642,000 |
|
Chargebacks [Member]
|
|
|
| Roll forward of each significant accounts receivable estimate |
|
|
| Valuation Allowances and Reserves, Balance, Beginning Balance |
10,477,000 |
8,588,000 |
| Current Provision |
70,222,000 |
64,884,000 |
| Actual Credits in Current Period |
(70,458,000) |
(64,065,000) |
| Valuation Allowances and Reserves, Balance, Ending Balance |
10,241,000 |
9,407,000 |
|
Sales discounts [Member]
|
|
|
| Roll forward of each significant accounts receivable estimate |
|
|
| Valuation Allowances and Reserves, Balance, Beginning Balance |
1,813,000 |
2,353,000 |
| Current Provision |
4,555,000 |
4,349,000 |
| Actual Credits in Current Period |
(4,214,000) |
(4,842,000) |
| Valuation Allowances and Reserves, Balance, Ending Balance |
2,154,000 |
1,860,000 |
|
Sales allowances & returns [Member]
|
|
|
| Roll forward of each significant accounts receivable estimate |
|
|
| Valuation Allowances and Reserves, Balance, Beginning Balance |
5,745,000 |
6,159,000 |
| Current Provision |
25,516,000 |
17,650,000 |
| Actual Credits in Current Period |
(22,307,000) |
(16,434,000) |
| Valuation Allowances and Reserves, Balance, Ending Balance |
$ 8,954,000 |
$ 7,375,000 |
| X |
- Definition
Valuation allowances and reserves current provision.
+ References+ Details
| Name: |
hitk_ValuationAllowancesAndReservesCurrentProvision |
| Namespace Prefix: |
hitk_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
duration |
|
| X |
- Details
| Name: |
us-gaap_AccountsNotesAndLoansReceivableNetCurrentAbstract |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:stringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 09
-Article 12
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e24092-122690
+ Details
| Name: |
us-gaap_ValuationAllowancesAndReservesBalance |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
instant |
|
| X |
- Definition
Total increases or decreases in allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e24092-122690
+ Details
| Name: |
us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
This web site and associated pages are not associated with, endorsed by, or sponsored by HI TECH PHARMACAL CO INC and has no official or unofficial affiliation with HI TECH PHARMACAL CO INC
Based on public records. Inadvertent errors are possible.
Faqs.org does not guarantee the accuracy or timeliness of any information on this site. Use at your own risk.
This website is not associated with the SEC
Some parts © 2013 Advameg, Inc.
|
|
